However, SGLT2 inhibitors currently block less than 50% of renal glucose resorption in healthy individuals; the urine glucose levels are maintained by SGLT2 and do not increase even in patients with diabetes (List et al., 2009; Liu et al., 2012). The gene discussed is SLC5A2; the disease is diabetes mellitus.